|
||
| |||||||
|
|
Keele, UK, 2nd
May 2006 - Cobra
Biomanufacturing Plc (AIM:CBF) today announced its
agreement with the International AIDS Vaccine Initiative (IAVI) and
GlaxoSmithKline Biologicals S.A. (GSK Biologicals), for process
development and manufacturing of two HIV vaccine candidates for
evaluation in clinical trials. The programme is in support of a
previously announced collaboration between IAVI and GSK.
The vaccine candidates
incorporate non-human primate adenovirus vectors. Leveraging Cobra’s
expertise in adenovirus manufacture and related process development
expertise, the work will be performed at Cobra’s Oxford and Keele
facilities.
Commenting on the contract, David Thatcher, CEO at Cobra, said: “We are very pleased to have been awarded this new manufacturing contract by two such renowned organisations at the forefront of AIDS clinical research. It validates our manufacturing expertise with virus products and will contribute significantly to building our revenue stream over 2006 and 2007.”
The non-human primate
adenovirus vector technology was derived from research conducted by
scientists at the University of Pennsylvania. The technology is owned
by the University and is exclusively licensed to GSK. Financial terms
of the agreement were not disclosed.
-Ends-
For further
information please contact:
Cobra Biomanufacturing Plc David Thatcher, Chief Executive Officer, Tel: + 44 (0) 1782 714181 Northbank Communications Marc Egelhofer, Tel: 44 (0) 1260 296 500 Buchanan Communications Tim Anderson / Mark Court / Rebecca Skye Dietrich, Tel: 44 (0) 207 466 5000
About Cobra
Biomanufacturing Plc
Cobra Biomanufacturing Plc
is a leading international manufacturer of biopharmaceuticals to the
lifescience industry. Founded in 1992, Cobra provides innovative
manufacturing solutions to the biopharmaceutical industry covering
DNA, virus, cellular therapeutics and recombinant protein products.
Cobra was the first company to develop GMP (Good Manufacturing
Practice) standard DNA manufacture in Europe, with specific expertise
in DNA medicines.
A range of unique, patented technologies, underpins this revenue generating business.
Cobra floated on the
Alternative Investment Market of the London Stock Exchange in June
2002 raising £7 million and raised a further £5.2 million in May 2003
in order to further expand capacity in Oxford UK.
www.cobrabio.com
|
| ||||||||||
|
